Idorsia – Reaching out for more
The following information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”, “pending” or “anticipates” or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company’s investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company’s existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
“We have one simple vision: creating a sustainable mid-size pharma company based on innovation”

Jean-Paul Clozel
Chief Executive Officer
The origin of Idorsia
USD 30 Billion acquisition of Actelion – Idorsia is born

Marketed products – PAH franchise, late-stage pipeline with royalties to Idorsia, option to license aprocitentan

All research projects and early-stage pipeline
Idorsia today: A 3-year-old biotech with a 20-year heritage
Becoming a sustainable mid-size pharma company

We know what it takes

Drug discovery engine
Rich pipeline
Global commercial organization
Strong liquidity
Despite COVID-19, Idorsia made progress on all fronts in 2020.
Our drug discovery engine

- Focus on small molecules
- Single-center approach
- 380 researchers
- Discovering 2 – 3 New Chemical Entities (NCE) / year
- Home-grown pipeline
A rich development pipeline

<table>
<thead>
<tr>
<th>Compound</th>
<th>Mechanism of Action</th>
<th>Target Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daridorexant</td>
<td>Dual orexin receptor antagonist</td>
<td>Insomnia</td>
</tr>
<tr>
<td>Aprocitentan*</td>
<td>Dual endothelin receptor antagonist</td>
<td>Resistant hypertension management</td>
</tr>
<tr>
<td>Clazosentan</td>
<td>Endothelin receptor antagonist</td>
<td>Vasospasm associated with aneurysmal subarachnoid hemorrhage</td>
</tr>
<tr>
<td>Lucerastat</td>
<td>Glucosylceramide synthase inhibitor</td>
<td>Fabry disease</td>
</tr>
<tr>
<td>Selatogrel</td>
<td>P2Y$_{12}$ receptor antagonist</td>
<td>Suspected acute myocardial infarction</td>
</tr>
<tr>
<td>Cenerimod</td>
<td>S1P$_{1}$ receptor modulator</td>
<td>Systemic lupus erythematosus</td>
</tr>
<tr>
<td>ACT-774312</td>
<td>CRTH2 receptor antagonist</td>
<td>Nasal polyposis</td>
</tr>
<tr>
<td>ACT-539313</td>
<td>Selective orexin 1 receptor antagonist</td>
<td>Psychiatric disorders</td>
</tr>
<tr>
<td>Sinbaglustat</td>
<td>GBA2/GCS inhibitor</td>
<td>Rare lysosomal storage disorders</td>
</tr>
<tr>
<td>ACT-1004-1239</td>
<td>CXCR7 antagonist</td>
<td>Immunology / Cancer immunotherapy</td>
</tr>
<tr>
<td>ACT-1014-6470</td>
<td>-</td>
<td>Immunology</td>
</tr>
<tr>
<td>ACT-541478</td>
<td>-</td>
<td>CNS</td>
</tr>
</tbody>
</table>

* In collaboration with Janssen Biotech to jointly develop aprocitentan, Janssen Biotech has sole commercialization rights worldwide.

Neurocrine Biosciences has a global license to develop and commercialize our ACT-709478, a novel T-type calcium channel blocker, for the treatment of a rare form of pediatric epilepsy. In November 2020, Neurocrine announced it had initiated a Phase 2 study for ACT-709478.
Daridorexant
Insomnia market
Large opportunity in a highly unsatisfied market

- ~10% of adults suffer from insomnia
- 16 million treated patients in the US alone
- 1.5 billion USD is 5% of the insomnia market at suvorexant list price
- 200+ billion USD cost of insomnia to the US economy
- Almost all generic
  - Decline in z-drug use since 2013 FDA warnings
  - Corresponding increase in off-label trazodone use
- At least 14 years of patent life for daridorexant
Daridorexant – Phase 3 registration program

Revolutionizing the treatment of insomnia

Efficacy during the night and the day

- Sleep onset
- Sleep maintenance
- Total sleep time
- Daytime functioning

Safety and tolerability profile consistent between both pivotal studies

- No dose-dependent treatment emergent adverse events
- Low rate of clinically relevant adverse events
- No next morning hang-over effect
- No sign of rebound insomnia
- No withdrawal symptoms

Daridorexant is investigational, in development and not approved or marketed in any country.
Different by design – next generation DORA
Optimized pharmacokinetic profile

- Fast absorption
- Optimal half-life (8 h)
- No accumulation over time
- No active metabolites

Daridorexant is investigational, in development and not approved or marketed in any country.
Different by design – next generation DORA

$C_{max}$ – normalized concentration-time profiles

Terminal elimination half-life:
- Suvorexant 12 h
- Lemborexant 55 h
- Daridorexant 8 h
- Seltorexant 2.5 h

$C_{max}$ = maximum plasma concentration.
The data on the basis of which these profiles were constructed are taken from scientific publication.

Daridorexant is investigational, in development and not approved or marketed in any country.
Advancing towards registration

- Two pivotal Phase 3 studies with **positive results**
- Long-term efficacy and safety confirmed
- Very large clinical pharmacology program completed
- Phase 3 in Japan initiated with Mochida
- New drug application (**NDA**) submitted to US FDA
- Commercial pre-launch activity will begin in H1 2021
- European MAA submission planned for H1 2021

Daridorexant is investigational, in development and not approved or marketed in any country.
Clazosentan
Aneurysmal subarachnoid hemorrhage (aSAH)
A sudden life-threatening bleeding occurring in the subarachnoid space
Cerebral vasospasm post-aSAH

Occurs between 4 and 14 days after aSAH securing

Baseline aSAH: normal MCA

7 day after SAH: cerebral vasospasm
Japanese clazosentan registration program

Significant effect on primary endpoint: Incidence of vasospasm-related morbidity and all-cause mortality

### Event Rate (%)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Event Rate (%)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo (n=111)</td>
<td>28.8</td>
<td>0.0055</td>
</tr>
<tr>
<td>Clazosentan 10 mg/h (n=103)</td>
<td>13.6</td>
<td></td>
</tr>
<tr>
<td>Placebo (n=106)</td>
<td>39.6</td>
<td>0.0001</td>
</tr>
<tr>
<td>Clazosentan 10 mg/h (n=105)</td>
<td>16.2</td>
<td></td>
</tr>
</tbody>
</table>

Full Analysis Set
Statistical test: Cochran-Mantel-Haenszel test stratified by WFNS Grade (pre-procedure)

No unexpected safety findings. TEAEs occurring >5% in the clazosentan group with a difference of >2% compared to placebo were vomiting and signs of hemodilution or fluid retention.

Clazosentan is investigational, in development and not approved or marketed in any country.

J.P. Morgan Healthcare Conference | 12 Jan 2021
Clazosentan in CONSCIOUS-3 study

Exploratory analysis* 15mg/hr showed significant effect on morbidity / mortality

*Recruitment into CONSCIOUS 3 was concluded early in October 2010

Clazosentan is investigational, in development and not approved or marketed in any country.

Stroke. 2012; 43(6):1463-9

Randomized Trial of Clazosentan in Patients With Aneurysmal Subarachnoid Hemorrhage Undergoing Endovascular Coiling

R. Loch Macdonald, MD, PhD; Randall T. Higashida, MD; Emmelina Keller, MD; Stephan A. Mayer, MD; Andy Molyneux, MD; Andreas Rabe, MD; Peter Vajkoczy, MD; Isabel Wantke, MD; Doris Bach, MSc; Alina Frey, PharmD; Régis Newsbihr, PhD; Sébastien Roex, MD; Ned Kassell, MD

Stroke. 2012; 43(6):1463-9
Selatogrel
Selatogrel for subcutaneous self-administration

The “Cardiac Pen”

>800,000 heart attacks in the US every year

8.4 million survivors

According to the American Heart Association, there are currently 8.4 million heart attack survivors in the US

Special Protocol Assessment (SPA) has been agreed with the FDA

“fast-track” designation from FDA received

SOS-AMI: Phase 3 study with 14’000 patients expected to be initiated in H1 2021

Selatogrel is investigational, in development and not approved or marketed in any country.

J.P. Morgan Healthcare Conference | 12 Jan 2021
Phase 2 data with selatogrel

Selatogrel has a rapid PD effect following subcutaneous injection

- Subcutaneous administration of selatogrel 8 mg and 16 mg has demonstrated a rapid onset of action, **within 15 minutes**, with the height of its effect **extending over 4-8 hours**, depending on the dose.

- Selatogrel was **safe and well tolerated** in both studies and there were no treatment-emergent serious bleeds.

Selatogrel is investigational, in development and not approved or marketed in any country.
Additional major achievements in 2020

Late-stage pipeline advancing

MODIFY: lucerastat
recruitment completed

PRECISION: aprocitentan
recruitment nearing completion – within days!

REACT: clazosentan in EU/US
recruitment halfway completed

CARE: cenerimod
recruitment to be completed end-Feb

All these projects faced multiple DSMB reviews with no drug-related safety signals flagged

Lucerastat, clazosentan, aprocitentan, and cenerimod are investigational, in development and not approved or marketed in any country.
Idorsia is at an inflection point with major catalysts expected in the near-term

**Daridorexant**
- **FILING:** US FDA followed by EMA

**Clazosentan**
- **FILING:** Japan

**Selatogrel**
- **INITIATION:** Phase 3 "SOS-AMI"

**Lucerastat**
- **DATA:** Phase 3 "MODIFY"

**Cenerimod**
- **DATA:** Phase 2b "CARE"

**Daridorexant**
- **APPROVAL & commercial LAUNCH**

**Aprocitentan**
- **DATA:** Phase 3 "PRECISION"

**Clazosentan**
- **APPROVAL & commercial LAUNCH in JAPAN**

**Clazosentan**
- **DATA:** Phase 3 "REACT"
Building a commercial organization

Chief Commercial Officer
Simon Jose

Global Product Strategy

- President, Idorsia US
  Patty Torr
- President, Idorsia Japan
  Satoshi Tanaka
- Head of Global Marketing
  Rebecca Weil
- Head of Global Market Access
  Christophe Segalini
- Head of Global Supply Chain
  Olivier Nalinne

President, Europe & Canada
Feb 1st start

Global Product Strategy

Key partners fully engaged

Syneos Health
Omnipcom Group
ruder finn
2021 will be a key year for Idorsia

Enter 2021 with a strong balance sheet (liquidity + undrawn credit facility from J&J)

- Filing of daridorexant in the US and EU
- PDUFA of Ponesimod for J&J
  Idorsia has a revenue-sharing agreement in respect to ponesimod
- Filing of clazosentan in Japan
- Start Phase 3 (under SPA) for selatogrel
- Phase 3 results for lucerastat in Fabry disease
- Phase 2b results for cenerimod in SLE
Idorsia revenues in the future

Net sales
- **GP Product:** Daridorexant
- **Orphan:** Lucerastat, clazosentan
- **Specialty:** Cenerimod, selatogrel

Rich pipeline allows substantial leverage of the commercial organization

Royalty streams
- Ponesimod
- Aprocitentan
- T-type calcium channel blocker
“2021 will be key for our vision to build a sustainable mid-sized pharmaceutical company”

Jean-Paul Clozel
Chief Executive Officer
Be prepared for more!